Same semaglutide. Different box, different dose ceiling, different insurance headache. Here's what actually matters.
Bottom line: They are the same drug. The real differences are: (1) maximum dose, Wegovy caps at 2.4 mg standard and 7.2 mg with Wegovy HD, while Ozempic caps at 2.0 mg; (2) FDA indication and which insurance checkbox gets ticked; (3) pen design, multi-dose dial vs single-dose auto-injector; (4) Wegovy carries an explicit cardiovascular risk reduction label from SELECT; (5) Wegovy now has an oral formulation. If you have T2D, Ozempic is easier to get covered. If weight loss is the goal, Wegovy's higher dose ceiling and dedicated indication make it the purpose-built tool. The molecule underneath is identical.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide, max 2.0 mg/week (injectable) | Semaglutide, max 2.4 mg/week standard; max 7.2 mg/week (Wegovy HD, approved March 2026) |
| FDA approval | Type 2 diabetes management (December 2017) | Chronic weight management (June 2021). Cardiovascular risk reduction added 2024. Oral Wegovy (25 mg tablet) approved January 2026. |
| Max approved dose | 2.0 mg once weekly. This is the ceiling. No approved pathway to go higher. | 2.4 mg once weekly standard. Wegovy HD: 7.2 mg once weekly for patients who don't respond adequately at 2.4 mg. STEP UP trial: 20.7% mean weight loss. |
| Titration schedule | 4 steps over ~16 weeks: 0.25, 0.5, 1.0, 2.0 mg | 5 steps over ~20 weeks: 0.25, 0.5, 1.0, 1.7, 2.4 mg. Wegovy HD has an extended titration beyond this. |
| Pen device | Multi-dose pen with a dose dial. One pen lasts ~4 weeks at a maintenance dose. | Single-dose prefilled auto-injector. One pen per weekly injection at maintenance. Wegovy HD uses its own dedicated pen. |
| Weight loss data | STEP 2 (T2D patients, 1.0 mg): ~9.6% body weight reduction at 68 weeks vs 3.4% placebo (PMID: 33667417). Ozempic was not tested at 2.4 mg in weight loss trials. | STEP 1 (non-diabetic, 2.4 mg): ~14.9% body weight reduction at 68 weeks vs 2.4% placebo (PMID: 33567185). Wegovy HD: 20.7% in STEP UP trial. |
| Cardiovascular benefit | SELECT trial used 2.4 mg dosing, Wegovy's dose, not Ozempic's. Ozempic has no CV outcomes trial at its approved ceiling dose. | SELECT trial (PMID: 37952131): 20% reduction in MACE in adults with obesity/overweight and established CVD, no diabetes. FDA added CV risk reduction to Wegovy's label in 2024. This indication is Wegovy-only. |
| Insurance coverage | Widely covered by commercial plans for T2D. Off-label weight loss use is frequently denied. | Only ~1 in 4 commercial plans covered Wegovy for weight loss as of early 2026. Medicare GLP-1 Bridge Program launched July 2026: $50 copay for eligible Part D beneficiaries. |
| Price without insurance | ~$968/month (US list price, 2026) | ~$1,349/month standard (2026). Wegovy HD pricing not yet established. |
| Oral option | No oral Ozempic. Rybelsus (oral semaglutide, 3-14 mg daily) is a separate T2D product. | Oral Wegovy (25 mg tablet once daily) FDA-approved January 2026 for weight management. First oral GLP-1 approved specifically for obesity. |
| Compounded access | FDA removed semaglutide from the shortage list February 2025. 503A pharmacies may still compound for individual patients with documented clinical need. 503B bulk compounding effectively banned. | Same regulatory status. Same molecule, same shortage resolution. No brand distinction exists for compounding purposes. |
| What is literally identical | Mechanism (GLP-1 receptor agonist), half-life (~7 days), injection frequency (once weekly), side effect profile, and contraindications (MTC/MEN2 history). | Mechanism (GLP-1 receptor agonist), half-life (~7 days), injection frequency (once weekly), side effect profile, and contraindications (MTC/MEN2 history). |
tierA: {"tier":1,"label":"Phase 3 complete, FDA-approved, cardiovascular CVOT (at Wegovy dose)"}
tierB: {"tier":1,"label":"Phase 3 complete, FDA-approved, dedicated obesity indication + CV label"}
summary: Semaglutide has one of the deepest clinical evidence bases of any weight-management drug. STEP 1-5 trials, SELECT cardiovascular outcomes trial, and STEP UP (7.2 mg) collectively cover >30,000 patients across multiple populations. All efficacy differences between Ozempic and Wegovy are dose-driven, not brand-driven.
trials: [{"name":"STEP 1 (Wegovy 2.4 mg)","peptide":"b","n":"1961","finding":"14.9% mean weight loss at 68 weeks vs 2.4% placebo","pmid":"33567185"},{"name":"STEP 2 (T2D patients, 1.0 mg)","peptide":"a","n":"1210","finding":"9.6% weight loss at 68 weeks vs 3.4% placebo. Ozempic dose range.","pmid":"33667417"},{"name":"SELECT (cardiovascular, 2.4 mg)","peptide":"b","n":"17604","finding":"20% reduction in MACE in patients with obesity + CVD, no diabetes. Wegovy-level dosing.","pmid":"37952131"},{"name":"STEP 1 Extension (withdrawal)","peptide":"b","n":"327","finding":"~11.6 percentage points of weight regained within 52 weeks of stopping semaglutide.","pmid":"35441470"},{"name":"STEP UP (Wegovy HD 7.2 mg)","peptide":"b","n":"TBD","finding":"20.7% mean weight loss. ~1 in 3 patients achieved 25%+ loss. Approved March 2026."}]
{"applies":false,"name":"Same drug. Don't double it.","intro":"","phases":[],"note":"Ozempic and Wegovy cannot and should not be combined. They are the same molecule. Using both simultaneously is doubling your semaglutide dose without supervision. There is no stacking protocol for two brands of the same drug."}
Pharma pricing is set by the manufacturer, not by the molecule. Novo Nordisk priced Wegovy higher for the weight-loss market. It uses a dedicated single-dose pen and carries a separate FDA indication. The price difference has zero pharmacological justification.
Yes. Off-label prescribing is legal in the US. Many providers do exactly this, particularly when Wegovy isn't covered by insurance. Whether your plan covers the off-label use is a separate question. Many won't.
Wegovy HD is semaglutide 7.2 mg, FDA-approved March 2026 for patients who don't achieve adequate response at 2.4 mg. Not a starter product. STEP UP trial showed 20.7% mean weight loss. It extends the semaglutide dose ceiling well beyond what Ozempic can reach.
No. Rybelsus (3-14 mg daily) is oral semaglutide approved for T2D management. Oral Wegovy (25 mg daily) was FDA-approved in January 2026 specifically for weight management. Different formulations, different doses, different approved uses. They are not interchangeable.
Almost certainly yes. The STEP 1 extension study (PMID: 35441470) found patients regained ~11.6 percentage points of lost weight within 52 weeks of stopping. This is biology, not failure. The drug suppresses appetite while you take it. It applies equally whether you were on Ozempic or Wegovy.
In limited circumstances. The FDA shortage exception ended in April-May 2025. 503A pharmacies can still compound semaglutide for individual patients IF a prescriber documents why a commercially available product doesn't meet that patient's specific needs. The widespread telehealth compounding market of 2022-2024 is effectively over.
Limited coverage began July 1, 2026, through the CMS Medicare GLP-1 Bridge Program. A demonstration program covering Wegovy (injection and oral) for eligible Part D beneficiaries at a $50 copay. It is a temporary program, not a permanent Medicare benefit.
It's complicated. SELECT used 2.4 mg semaglutide, Wegovy's dose, not Ozempic's 2.0 mg ceiling. There is no cardiovascular outcomes trial at Ozempic's maximum dose in non-diabetic patients. The biological mechanism suggests benefit is dose-dependent, but the specific claim is only proven at 2.4 mg. Wegovy has the label. Ozempic does not.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
